CAMBRIDGE, MA - May 20, 2015 - MedVax Technologies, Inc. announces that its Chief Executive Officer, Robert Brooks, will be attending the Redefining Early Stage Investments (RESI) Conference on June 8th in Houston, Texas. The conference provides an opportunity for companies in the biotech and pharmaceutical industries to partner with the newest sources of capital. Attendees include philanthropic organizations, foundations, family offices, and academic institutions.
JLABS Collaborates with LSN and TMCx For the RESI Conference
Johnson and Johnson Innovation, JLABS (JLABS) is collaborating with Life Science Nation (LSN) and Texas Medical Center Accelerator (TMCx) to bring the Redefining Early Stage Investments (RESI) Conference to Houston. The conference will take place at TMCx, the TMC's 100,000+square-foot, state-of-the-art accelerator space.
About MedVax Technologies, Inc.
MedVax is a biopharmaceutical company discovering and commercializing cancer immunotherapy drugs. MedVax's portfolio includes: MX-225, an autologous P53 dendritic cell vaccine that completed two Phase IIa trials in Small Cell Lung Cancer (SCLC), and recurring breast cancer. The company is planning a Phase II SCLC combination trial with MX-225 and a PD-1 antibody. Another one of MedVax's drugs in clinic is MX-402 - a unique B-cell epitope HER-2 Peptide vaccine that had showed safety and strong signals of efficacy in an interim Phase I trial. Eight of twelve patients showed clinical benefit, with one patient in complete remission. MedVax's team is comprised of world renowned scientists and biotech industry professionals.
Cautionary Note on Forward-Looking Statements
This press release and any statements of representatives and partners of MedVax Technologies, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the U.S. federal securities laws. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors, many of which are beyond the Company's control. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
VP, Business Development & Public Relations
MEDVAX TECHNOLOGIES, INC.
Harvard Square, One Mifflin Place, Suite 400
Cambridge, MA 02138
Tel: (617) 674-7718 ~ Fax: (617) 674-7701
Source: MedVax Technologies, Inc.